In the acute phase of stroke, targeted clearance or inhibition of neutrophil infiltration—via delivery of anti-Ly6G antibodies or blockade of CXC chemokine receptor 2 (CXCR2) and very late antigen-4 (VLA-4)—can significantly improve neurological deficits and reduce infarct volume (78). The gene discussed is CXCR2; the disease is stroke disorder.